(NP (NP-COOD (NP Mineralocorticoids/NNPS) and/CC (NP mineralocorticoid/NN receptors/NNS)) (PP in/IN (NP (NP mononuclear/JJ leukocytes/NNS) (PP in/IN (NP (NP patients/NNS) (PP with/IN (NP pregnancy-induced/JJ hypertension/NN)))))) ./.)
(S (S-PRP (NP-SBJ *-48/-NONE-) (VP To/TO (VP examine/VB (NP (NP the/DT role/NN) (PP of/IN (NP mineralocorticoids/NNS)) (PP in/IN (NP (NP the/DT pathophysiology/NN) (PP of/IN (NP (NP pregnancy-induced/JJ hypertension/NN) (PRN -LRB-/-LRB- (NP PIH/NN) -RRB-/-RRB-))))))))) ,/, (NP-SBJ-48 we/PRP) (VP studied/VBD (NP (NP (NP-COOD (NP plasma/NN aldosterone/NN) and/CC (NP 18-hydroxycorticosterone/NN)) levels/NNS) (PP in/IN (NP-COOD (NP (NP 25/CD women/NNS) (PP with/IN (NP PIH/NN))) and/CC (NP (NP 25/CD normal/JJ pregnant/JJ women/NNS) ,/, (PP as/IN (NP controls/NNS))))))) ./.)
(S (ADVP Furthermore/RB) ,/, (NP-SBJ we/PRP) (VP evaluated/VBD (NP (NP (NP the/DT (NP (NP mineralocorticoid/NN receptor/NN) (PRN -LRB-/-LRB- (NP MR/NN) -RRB-/-RRB-)) status/NN) (PP in/IN (NP mononuclear/JJ leukocytes/NNS))) (PP in/IN (NP the/DT 2/CD groups/NNS)))) ./.)
(S (NP-SBJ-49 MR/NN count/NN) (VP was/VBD (ADVP significantly/RB) (PRN -LRB-/-LRB- (S (NP-SBJ P/NN) (NP-PRD (QP less/JJR than/IN 0.0005/CD))) -RRB-/-RRB-) (VP decreased/VBN (NP *-49/-NONE-) (PP in/IN (NP (NP the/DT PIH/NN group/NN) (PRN -LRB-/-LRB- (FRAG (NP (QP 148/CD +\/-/CC 9/CD) binding/VBG sites\/cell/NNS)) -RRB-/-RRB-))) (PP compared/VBN (PP with/IN (NP (NP the/DT control/NN group/NN) (PRN -LRB-/-LRB- (FRAG (NP (NP (QP 300/CD +\/-/CC 17/CD) binding/VBG sites\/cell/NNS) ;/: (NP mean/NN +\/-/CC SEM/NN))) -RRB-/-RRB-)))))) ./.)
(S (S (NP-SBJ (NP Plasma/NN aldosterone/NN) (PP in/IN (NP (NP women/NNS) (PP with/IN (NP PIH/NN))))) (VP was/VBD (NP-PRD (QP 281/CD +\/-/CC 61/CD) pmol\/L/NN)) ;/:) (S (PP in/IN (NP normal/JJ pregnant/JJ women/NNS)) (NP-SBJ it/PRP) (VP was/VBD (NP-PRD (QP 697/CD +\/-/CC 172/CD) pmol\/L/NN) (PRN -LRB-/-LRB- (S (NP-SBJ P/NN) (NP-PRD (QP less/JJR than/IN 0.025/CD))) -RRB-/-RRB-)) ./.))
(S (NP-SBJ Plasma/NN 18-hydroxycorticosterone/NN) (VP was/VBD (ADVP also/RB) (ADJP-PRD (ADJP significantly/RB (PRN -LRB-/-LRB- (S (NP-SBJ P/NN) (NP-PRD (QP less/JJR than/IN 0.025/CD))) -RRB-/-RRB-) lower/JJR) (PRN -LRB-/-LRB- (FRAG-COOD (FRAG (NP PIH/NN) ,/, (NP (QP 1071/CD +\/-/CC 149/CD) pmol\/L/NN)) ;/: (FRAG (NP controls/NNS) ,/, (NP (QP 1907/CD +\/-/CC 318/CD) pmol\/L/NN))) -RRB-/-RRB-))) ./.)
(S (NP-SBJ-50 These/DT values/NNS) (VP were/VBD (VP determined/VBN (NP *-50/-NONE-) (PP-TMP at/IN (NP (NP the/DT onset/NN) (PP of/IN (NP (NP clinical/JJ symptoms/NNS) (PP of/IN (NP PIH/NN)))))))) ./.)
(S (S (NP-SBJ-51 These/DT results/NNS) (VP can/MD not/RB (VP be/VB (VP explained/VBN (NP *-51/-NONE-) (PP by/IN (NP-LGS (NP receptor/NN down-regulation/NN) (PP due/JJ to/TO (NP (NP higher/JJR levels/NNS) (PP of/IN (NP (NP mineralocorticoids/NNS) (PP in/IN (NP PIH/NN))))))))))) ;/:) (S (NP-SBJ a/DT (ADJP hitherto/RB unknown/JJ) mineralocorticoid/NN) (VP may/MD ,/, (ADVP thus/RB) ,/, (VP be/VB (ADJP-PRD responsible/JJ (PP for/IN (NP the/DT (NP-COOD (NP hypertension/NN) and/CC (NP altered/JJ MR/NN)) status/NN))))) ./.))
